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Background: Cholangiocarcinoma (CC) is a primary liver cancer with increasing incidence worldwide. Despite all
efforts made in past years, prognosis remains to be poor. At least in part, this might be explained by a pronounced
resistance of CC cells to undergo apoptosis. Thus, new therapeutic strategies are imperatively required. In this study
we investigated the effect of Salinomycin, a polyether ionophore antibiotic, on CC cells as an appropriate agent to
treat CC. Salinomycin was quite recently identified to induce apoptosis in cancer stem cells and to overcome
apoptosis-resistance in several leukemia-cells and other cancer cell lines of different origin.
Methods: To delineate the effects of Salinomycin on CC, we established an in vitro cell culture model using three
different human CC cell lines. After treatment apoptosis as well as migration and proliferation behavior was
assessed and additional cell cycle analyses were performed by flowcytometry.
Results: By demonstrating Annexin V and TUNEL positivity of human CC cells, we provide evidence that
Salinomycin reveals the capacity to break apoptosis-resistance in CC cells. Furthermore, we are able to demonstrate
that the non-apoptotic cell fraction is characterized by sustainable impaired migration and proliferation. Cell cycle
analyses revealed G2-phase accumulation of human CC cells after treatment with Salinomycin. Even though
apoptosis is induced in two of three cell lines of CC cells, one cell line remained unaffected in regard of apoptosis
but revealed as the other CC cells decreased proliferation and migration.
Conclusion: In this study, we are able to demonstrate that Salinomycin is an effective agent against previously
resistant CC cells and might be a potential candidate for the treatment of CC in the future.
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Cholangiocarcinoma (CC) is an adenocarcinoma arising
from the biliary epithelial cells and can affect both the
intra- and extrahepatic biliary tree [1]. Beside hepatocel-
lular carcinoma (HCC) it is the most common liver can-
cer with increasing incidence over the past years [2-4].
While in Asian countries the high incidence of CC is
associated with liver flukes also in Northern America
and Europe intrahepatic CC occurs in increasing num-
ber of unknown reason [4]. Patient´s survival is drama-
tically restricted due to limited treatment options and
advanced stage of disease at presentation [5]. Thus* Correspondence: klose.johannes@mh-hannover.de
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reproduction in any medium, provided the ortreatment of CC is currently one of the biggest chal-
lenges in modern oncology. The only curative treatment
options for this kind of cancer are radical surgical resec-
tion or as performed in some centers for a selected sub-
set of patients liver transplantation [5,6]. Chemotherapy
is less effective; however, a new protocol combining
Gemcitabine and Cisplatin might be a promising thera-
peutical strategy for patients with advanced CC [7]. Lim-
ited data is available on the exact pathomechanisms
leading to the development of CC. Chronic inflamma-
tory conditions, such as primary sclerosing cholangitis,
congenital biliary disorders, infection with liver flukes or
toxic agents are supposed to be related to the malignant
transformation of the biliary epithelial cells [8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lated from Streptomyces albus [9]. It acts as a potassium
ionophore and thereby interferes with transmembrane
potassium potential, leading to mitochondrial and cellu-
lar potassium efflux [10,11]. Salinomycin is widely-used
as an anticoccidial in poultry [12] and as a dietary sup-
plement in ruminants` and pigs` breed [13,14]. Recently,
the potential of Salinomycin as an anti-cancer agent has
been elucidated [15]. First, the effects of Salinomycin
were described in the treatment of cancer stem cells
in vitro and in vivo [16]. Later, the efficacy of Salinomy-
cin against tumor cells has been demonstrated in several
cancer cell lines from different origin, including solid
and non-solid malignancies [17-20]. Nevertheless, the
precise mode of action of Salinomycin as an anti-cancer
agent remains unclear.
So far, the impact of Salinomycin treatment on human
CC cells has not been investigated. Thus, the aim of the
present study was to investigate whether the anti-cancer
effect of Salinomycin is also sufficient for the treatment
of CC. We identified that Salinomycin induces apoptosis
in human CC cells in vitro. In addition, we demonstrate
that Salinomycin impairs tumor cell migration, reduces
tumor cell proliferation and leads to cell cycle accumula-
tion. Our data provide that treatment of human CC cells
with Salinomycin has a promising anti-cancer effect.Methods
Cell lines and culture
For proof of principle of the properties of Salinomycin
the reactivity of three well characterized human CC cell
lines, Mz-ChA-1 , TFK-1 and EGI-1 [21-23] was tested.
Cells were cultured at 37°C and 5% CO2 in culture
medium (RPMI 1640 + Glutamax, supplemented with
10% fetal bovine serum, 10 mM HEPES-Buffer, 1%
MEM non-essential Amino acids, penicillin (50 U/ml),
and streptomycin (50 mg/l)) (Invitrogen, Darmstadt,
Germany). Medium was changed every 48 hours. Mz-
ChA-1 cells were a kind gift from Dr. A Knuth (Univer-
sitiy Hospital of Zurich, Zurich, Switzerland). TFK-1 and
EGI-1 cells were provided by S. Zender (Hannover
Medical School, Hannover, Germany). Jurkat cells were
cultured in RPMI 1640, supplemented with 10% fetal
bovine serum, penicillin (50 U/ml) and streptomycin
(50 mg/l), at 37°C and 5% CO2. Cells were maintained
by passages every 72 hours.Chemicals
Salinomycin was purchased from Sigma-Aldrich (Munich,
Germany) and dissolved in DMSO. Gemcitabine was pur-
chased from TEVA (Radebeul, Germany) and dissolved in
phosphate buffered saline (PBS). Stock solutions were
stored at −20°C.Proliferation assay
1 × 103 human CC cells were cultured in medium alone
or in the presence of 1 mM Gemcitabine, 1 μM, 2 μM,
5 μM or 10 μM Salinomycin in 96-well flat bottom
plates. The cultures were expanded for different time
periods: either 24 or 48 hours under treatment of
reagents respectively or first exposed to Gemcitabine
and Salinomycin for 48 hours followed by additional 48
hours in medium alone. For the last 16 hours of culture
cells were pulsed with 1 μCi 3H-Thymidine and incorp-
oration was assessed using a β-counter (LKB Wallac,
Turku, Finland).
Cell cycle analysis
Cell cycle analysis was performed using the CellTest
Plus Reagent Kit (Becton Dickinson Imunocytometry
Systems, San Jose, California, USA). 1 × 105 human CC
cells were seeded in 12-well plates for 24 hours without
reagents to allow attachment. Cells were then incubated
in the presence or absence of 1 mM Gemcitabine, 1 μM,
2 μM, 5 μM or 10 μM Salinomycin for 24 hours, trypsi-
nized and stained according to the manufacturer´s
instructions. Analysis was performed using a FACSCali-
bur (BD Bioscience, Heidelberg, Germany) and the
ModFit LD software (Verity House Software, Topsham,
Maine, USA).
Migration assay
Tumor cell migration was analyzed using a transwell
chamber (Corning Coster, Corning, NY, USA) provided
with an 8 μm pore polycarbonate membrane. Human
CC cells were placed at 5 × 105 cells/well in culture
medium containing 10% fetal calf serum in the upper
compartment of the chamber. The lower compartment
was filled with culture medium containing 30% fetal calf
serum acting as a chemo-attractant [24]. Cells were cul-
tured in the absence or presence of 1 mM Gemcitabine,
1 μM, 2 μM, 5 μM or 10 μM Salinomycin for 48 hours.
The membrane was then removed, fixed with ethanol
and stained with hematoxylin. The membranes were
analyzed under a light microscope counting the number
of migrated cells to the lower surface of the membrane
in five randomly selected fields as described before [25].
Annexin V analysis
Human CC cells were plated in 6-well plates at 1 × 106
cells/well in culture medium and grown until conflu-
ence. Cells were further incubated in the presence or ab-
sence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or
10 μM Salinomycin for 24 hours. Cells were trypsinized
and washed two times with PBS. Induction of apoptosis
was assessed using Annexin V apoptosis detection kit
(BD Biosciences, Heidelberg, Germany) according to the
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with a FACSCalibur (BD Biosciences).
Terminal desoxynucleotidyl transferase (dUTP) nick end
labeling (TUNEL) assay
3 × 104 human CC cells were cultured in 8-well glass
chamber slides (Nunc, Rochester, NY, USA) until conflu-
ence in medium alone and further on for 24 hours in
the absence or presence of 1 mM Gemcitabine, 1 μM,
2 μM, 5 μM or 10 μM Salinomycin. Cells were fixed
with 4% paraformaldehyde for 25 min at 4°, washed with
PBS and permeabilized by methanol/acetone solution for
10 min. Cells were equilibrated with equilibration buffer
(Promega, Madison, Wisconsin, USA) for 5–10 min at
room temperature. After washing with PBS cells were
incubated with rTDT incubation buffer for 60 min at
37°. Reaction was stopped with 20x concentrated SSC
buffer and washed with PBS. Nuclei staining was per-
formed by adding DAPI 1:2500 (Sigma, St. Louis,
Missouri, USA) in PBS during the final washing
procedure. Cells were mounted in VECTASHIELD and
analyzed within 24 hours. TUNEL assay was performed
using a commercial kit (Promega, Madison, Wisconsin,
USA).
Immunocytochemistry
3 × 104 adherent human CC cells were cultured in cham-
ber slides in medium until confluence. Cells were further
cultured in the absence or presence of 1 mM Gemcita-
bine, 1 μM, 2 μM, 5 μM or 10 μM Salinomycin for
24 hours. Cells were fixed with 4% paraformaldehyde for
25 min at 4°, washed with PBS and air-dried for 1 hour.
As positive control for Caspase-dependent induction of
apoptosis human Jurkat cells were exposed to human
TRAIL-expressing transgenic fibroblasts for 12 hours.
Jurkat cells were subsequently washed from adherent
fibroblasts and air-dried on slides after cytospin centrifu-
gation (Shandon Cytospin GMI, Ramsay, Minnesota,
USA). All samples were fixed by acetone/methanol solu-
tion and afterwards air-dried for one hour. Analysis of
activated caspases was performed using a monoclonal
antibody against cleaved caspase-3 (New England Bio-
labs, Ipswich, Massachusetts, USA) diluted 1:200 in PBS.
Staining was visualized using Cy3-labeled secondary
donkey anti-rabbit antibody (Biolegend, San Diego,
California, USA) diluted 1:500 in PBS. Nuclei staining
was performed by adding DAPI 1:2500 in PBS during the
final washing procedure. Cells were analyzed using the
AxiolmagerM1 microscope (Zeiss, Jena, Germany) and
the AxioVision 4.6 software (Zeiss).
Statistical analysis
Results were expressed as mean ± SD. All experiments
were performed at least in three individual experiments.Results were analyzed for statistical significance using
two-way ANOVA test or student´s t-test.
Results
Exposure of Salinomycin to human CC cells provokes
morphological changes
The described human CC cell lines Mz-ChA-1, TFK-1
and EGI-1 were exposed to increasing concentrations of
Salinomycin (1 μM, 2 μM, 5 μM and 10 μM) for
24 hours. Gemcitabine as a broadly used chemothera-
peutic for the treatment of CC was used as an interven-
tional control in all performed experiments. After
treatment with Gemcitabine, Mz-ChA-1 cells appear-
ed swollen and grown in a cobblestone-like pattern
(Figure 1 A). The administration of Salinomycin also
altered the morphological appearance of the cells. While
low concentrations of Salinomycin of 1 μM and 2 μM
resulted in haggard and less confluent grown cells, in-
creasing concentrations of Salinomycin of 5 μM and 10
μM resulted in a globular and defragmented cellular
phenotype (Figure 1A). According to the results of ex-
posure of Mz-ChA-1 cells to Salinomycin, also TFK-1
cells reacted in a similar pattern (data not shown). In
contrast, exposure of Salinomycin to EGI-1 cells resulted
in less characteristic morphological changes. While after
treatment with 1 mM Gemcitabine, also swollen cells
could be observed (Figure 1B), treatment of EGI-1 cells
even with high concentrations of Salinomycin was ac-
companied by marginal morphological alterations and
the lack of pronounced cell destruction. To figure out if
the morphological changes of Mz-ChA-1 and TFk-1
cells are associated with an induction of apoptosis, we
assessed the presence of apoptotic cells by Annexin V
and TUNEL staining after treatment with Salinomycin.
Salinomycin induces apoptosis in human CC cells
The rate of Annexin V positive human CC cells was deter-
mined by flow cytometry. Annexin V positivity is a typical
attribute of apoptotic cells, thus an appropriate method to
quantify apoptosis. As demonstrated in Figure 2, increas-
ing concentrations of Salinomycin resulted in an increased
percentage of Annexin V-positive Mz-ChA-1 and TFK-1
cells up to 65% and 85%, respectively (see Figure 2). Treat-
ment with Gemcitabine resulted only in a low proportion
of apoptotic cells. Interestingly, the ability of Salinomycin
to induce apoptosis also in EGI-1 cells was noticeable
reduced (Figure 2). These data represent the differences in
the morphological appearance between Mz-ChA-1 and
EGI-1 cells.
To delineate the different outcomes of Salinomycin
treatment on MZ-ChA-1 and TFK-1 cells on one side
and EGI-1 cells on the other side, additional experi-
ments were performed to assess apoptotic cells by
TUNEL test. According to the detection of Annexin V-
Figure 1 Morphological changes after treatment with Salinomycin. 3 x 104 Mz-ChA-1 and EGI-1 cells were plated in chamber slides and
further cultured until confluence. Cells were subsequently incubated in the absence or presence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or
10 μM Salinomycin for 24 hours. (A): Effects of Gemcitabine and Salinomycin treatment on Mz-ChA-1 cells. Incubation of cells with 1 mM
Gemcitabine resulted in swollen and cobblestone-like appearance. In contrast the morphology of Mz-ChA-1 cells after treatment with low
concentration of Salinomycin is altered to a haggard image and less confluent cell growth dependent on the amount of added agent. This
appearance was further enhanced by higher concentration of 5 μM and 10 μM Salinomycin. (B): Treatment of EGI-1 cells with Salinomycin even
with 5 μM and 10 μM revealed increased tolerance of agent since indication of morphological damages were less distinct. 1 mM Gemcitabine
however caused comparable outcome on EGI-1 cells compared to Mz-ChA-1 and TFK-1 cells. Results are shown as representative pictures of one
out of 3 independent experiments.
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24 hours by flow cytometry, high concentrations of 5
μM and 10 μM Salinomycin led to increased number of
TUNEL-positive Mz-ChA-1 cells (Figure 3A). Elevated
levels of TUNEL-positive cells were not detected in Mz-
ChA-1 cells treated with Gemcitabine (Figure 3A). Simi-
lar findings were observed when TFK-1 cells were inves-
tigated (data not shown). In turn, TUNEL-positive
staining in EGI-1 cells was less impressive compared to
Mz-ChA-1 and TFK-1 cells (Figure 3B). These data are
consistent with our previous finding of less Annexin V-
positive EGI-1 cells.
Regarding that apoptosis is typically characterized by
an activation of caspases we investigated if induction of
apoptosis by Salinomycin in human CC cells is also ac-
companied by activated caspases. Therefore, we used a
monoclonal antibody against caspase-3. Interestingly,
activated caspase-3 was not found in Salinomycin-
induced apoptosis in human CC cells (Figure 3C). Nei-
ther incubation of Mz-ChA-1 cells with 5 μM nor with
10 μM Salinomycin resulted in an activation of caspase-
3. Also exposure of TFK-1 and EGI-1 cells to equivalentamounts of Salinomycin did not result in activated cas-
pase-3. A non-effectiveness of the staining procedure
was excluded by evidence of activated caspase-3 in apop-
totic Jurkat cells after exposure to human TRAIL
expressing transgenic fibroblasts (Figure 3C).
Impaired tumor cell migration after treatment with
Salinomycin
By demonstrating that Salinomycin induces apoptosis in
human CC cells, we went in further detail of impaired
cell function of CC cells after exposure to Salinomycin.
One provisory attitude of tumor cells is migration. To
delineate the ability of tumor cells to migrate from their
original localization and therewith to form metastases,
we investigated the ability of tumor cell migration in
human CC cells after treatment with Salinomycin in a
transwell chamber model. Mz-ChA-1, TFK-1 and EGI-1
cells were placed in transwell chambers provided with
an 8 μm pore polycarbonate membrane and incubated
with Salinomycin and Gemcitabine for 48 hours. Expos-
ure to high concentrations of Salinomycin of 5 μM and
10 μM resulted in impaired migration in all three cell
Figure 2 Salinomycin induces apoptosis in human CC cells. 1 x 106 Mz-ChA-1, TFK-1 and EGI-1 cells were cultured until confluence, followed
by subsequent incubation of cells in the absence or presence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or 10 μM Salinomycin for 24 hours. Cells
were trypsinized and stained with Annexin V-FITC and analyzed by flow cytometry. (A) As expected, treatment with Gemcitabine (dotted line in
overlay) led to very weak increase of apoptotic cells in all tested cell lines in comparison to untreated cells (solid bright line). In contrast,
Salinomycin induced strongly augmented number of apoptotic cells for Mz-ChA-1 and TFK-1, whereas EGI-1 cells revealed a pronounced
resistance towards Salinomycin-induced apoptosis (solid dark line). Results are shown as representative scatter-grams of Annexin V+ cells or
summarizing 3 independent experiments as mean ± SD (B).
Lieke et al. BMC Cancer 2012, 12:466 Page 5 of 12
http://www.biomedcentral.com/1471-2407/12/466lines (Figure 4). Notably, the amount of migrated cells
differed between the three different cell lines. These
results were statistically significant. Treatment with
Gemcitabine also resulted in impaired tumor cell migra-
tion. However, this difference was not significant. Conse-
quently, after demonstrating that treatment with
Salinomycin impairs tumor cell migration, we used the
3H-thymidine incorporation assay to assess if tumor cell
proliferation is also affected.
Enduring reduced proliferation of human CC cells after
treatment with Salinomycin
Mz-ChA-1, TFK-1 and EGI-1 cells were treated with Sali-
nomycin and Gemcitabine for 24 hours and 48 hours. Al-
ternatively, cell culture was extended after exposure to the
agents for 48 hours for an additional incubation period of
48 hours in medium alone. As demonstrated in Figure 5A,
cell proliferation was impaired in all three cell lines after
treatment with 1 mM Gemcitabine for 24 hours, due to the
described anti-proliferative properties of Gemcitabine.Proliferation of Mz-ChA-1 and TFK-1 cells was barely
impaired after exposure to Salinomycin for 24 hours. Inter-
estingly, only proliferation of EGI-1 cells was reduced after
exposure to high concentrations of Salinomycin of 5 μM
and 10 μM. After treatment with 1 mM Gemcitabine for
48 hours, cell proliferation was significantly reduced in all
three cell lines. Likewise, exposure to high concentrations
of Salinomycin of 5 μM and 10 μM for 48 hours to Mz-
ChA-1, TFK-1 and EGI-1 cells resulted in significantly
reduced cell proliferation (see Figure 5B). To further evalu-
ate the long-term effect of Salinomycin-administration to
human CC cells, after incubation with Salinomycin for 48
hours, medium supplemented with Salinomycin was
removed and the cells were further incubated for 48 hours
in fresh medium alone. As demonstrated in Figure 5C, pro-
liferation of human CC cells is sustainable reduced after in-
cubation with high concentrations of Salinomycin, even 48
hours after lapse of the agent. These results were statisti-
cally significant. Although an ongoing resistance to apop-
tosis induction in EGI-1 cells could be observed after
Figure 3 (See legend on next page.)
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Figure 3 Salinomycin induces apoptosis in human CC cells which is independent of activated caspases. 3 x 104 Mz-ChA-1 and EGI-1 cells
were plated in chamber slides, cultured until confluence and treated as described before. (A) TUNEL assay of Mz-ChA-1 cells confirmed induction
of apoptosis after exposure to increasing concentrations of Salinomycin whereas Gemcitabine failed to drive the cells into apotosis. (B)
Assessment of TUNEL-positive EGI-1 cells revealed the drastic reduced number of apoptotic cells for this cell line. (C) Analysis of expression of
Caspase-3 in Gemcitabine and Salinomycin treated Mz-ChA-1 cells. Although a distinct number of Mz-ChA-1 cells show apoptosis after
Salinomycin treatment, Caspase-3 was barely traceable in treated cells. To proof quality of reagents and methods we used Jurkat cells that were
exposed to TRAIL-expressing cells which induce reliable high percentages of apoptosis in Jurkat cells. Consequently a pronounced number of
Jurkat cells were Caspase-3 positive. Results are shown as representative pictures of one out of 3 independent experiments.
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comparable properties of the agent to impair cell function
of EGI-1 cells as observed in Mz-ChA-1 and TFK-1 cells.
This raises the question of a potential impact of Salinomy-
cin on the cell cycle of CC cells which in turn might explain
the differences in outcome following treatment of the dif-
ferent cell lines.
Salinomycin influences the cell cycle of human CC cells
Mz-ChA-1, TFK-1 and EGI-1 cells were exposed to Sali-
nomycin and to Gemcitabine for 24 hours. Cell cycle
evaluation was based on propidium iodide staining and
further analyzed using the ModFit LD software to assign
the flow cytometric measurement to a defined cell cycle
stage. As demonstrated in Figure 6, the cell cycle of un-
treated CC cells revealed a similar distribution for the
growth of the three CC cell lines. Treatment with Gem-
citabine resulted in an increased number of cells in the
S-phase in regard of Mz-ChA-1 and TFK-1 cells while
the cell cycle of EGI-1 cells did not alter in comparison
to untreated cells. Interestingly, EGI-1 cells maintained
the unaffected cell cycle even under treatment with high
concentrations of 5 μM and 10 μM of Salinomycin apart
from slight increase in the G1-phase after exposure to 5
μM Salinomycin. In contrast treatment of Mz-ChA-1
and TFK-1 cells resulted in drastic accumulation in the
G2- phase (Figure 6A and B).
Discussion
In this study we demonstrate that resistance to apoptosis
of CC cells can be overcome by treatment with Salino-
mycin. We show that two of three cell lines respond to
Salinomycin-treatment with a significant degree of apop-
tosis independent of Caspase-3 activity. In addition, Sali-
nomycin inhibits cell proliferation and cell migration. Of
note, this accounts for all three tested cell lines.
Patient´s survival suffering from CC is poor and even
CC calls for up to 15% of all primary liver malignancies,
the molecular pathogenesis is unclear to the greatest
possible extent [2-4,26]. Consequently, characterization
of the molecular pathogenesis and development of in-
novative therapeutic strategies are imperatively required
particularly since current approaches such as adminis-
tration of Gemcitabine combined with Cisplatin arerather part of a palliative concept than a curative treat-
ment strategy [7]. This is most likely due to apoptosis
resistance of CC cells and subsequently weak efficacy of
common chemotherapeutical regimes. The induction of
apoptosis in human CC cells is barely observed [25,27]
or only detectable after co-treatment of the cells with
additional drugs or inhibiting RNAs [28-30]. Accord-
ingly, the understanding and the therapy of CC are char-
acterized by nescience and ineffectiveness.
This is highlighted by the fact that even with Salinomy-
cin which revealed capacity to provoke apoptosis in two of
three tested human CC cell lines, EGI-1 remained to be
unaffected in terms of being predispositioned to apoptosis.
Exposure of Salinomycin to Mz-ChA-1 and TFK-1 cells,
which were both originally isolated from an extrahepatic
bile duct carcinoma [21,22], resulted in a high percentage
of apoptotic tumor cells, while EGI-1 cells seem to be less
susceptible for treatment with Salinomycin even after
treatment with high concentrations. It has been reported
that Salinomycin selectively affects malignant cells
whereas non-malignant cells do not undergo apoptosis
after treatment with Salinomycin [20,31,32]. Given that
EGI-1 cells are originally isolated from a poorly differen-
tiated human bile duct adenocarcinoma [23] and there-
with undoubted are malignant, it remains unclear why
these cells are nearly apoptosis-resistant to treatment with
Salinomycin. These observations demand further investi-
gations to elucidate potential escape mechanisms of tumor
cells which might be important for a possible clinical ap-
plication of Salinomycin in the future, indeed. Moreover,
apoptosis-escape mechanisms of EGI-1 cells might explain
in part the strong resistance of CC cells to chemothera-
peutics in general.
However, the exact mechanisms by which Salinomycin
induces apoptosis are still incomplete understood [15].
Salinomycin-induced apoptosis in human cancer cells is
mediated by an uncommon pathway and independent of
typical mechanism like activated caspases, death recep-
tors like the CD95/DC95 ligand system or tumor sup-
pressor protein p53 [15,19]. Demonstrating that
Salinomycin-induced apoptosis in human CC cells is in-
dependent of caspase-3 activation confirms that apop-
tosis is mediated through an uncommon pathway. Given
that caspase-3 is activated both in the extrinsic and
Figure 4 Impaired migration after treatment with Salinomycin. Tumor cell migration was analyzed using transwell chambers provided with
an 8 μm pore polycarbonate membrane. Mz-ChA-1, TFK-1 and EGI-1 cells were placed at 5 x 105 cells/well in culture medium containing 10%
fetal calf serum in the upper compartment of the chamber. As chemoattractant, the lower compartment was filled with culture medium
containing 30% fetal calf serum. Cells were cultured in the absence or presence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or 10 μM Salinomycin
for 48 hours. The membrane was then removed, fixed with ethanol and stained with hematoxylin. The membranes were analyzed under a light
microscope counting the number of migrated cells to the lower surface of the membrane in five random fields. Treatment with Salinomycin
resulted in impaired migration in all three tumor cell lines. Results are shown as representative pictures of light microscopic display (A) and as
mean ± SD (B) of 3 independent experiments. * p < 0,05 compared with control.
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role [33,34], it is astonishing that none of the common
pathways seems to be involved. Although activated
caspase-3 can be found in apoptotic CC cells after treat-
ment with Lobaplatin in vitro [35] another not yet dis-
covered apoptotic pathway appears to be responsible for
the effects of Salinomycin. Recently, it was reported that
the Wingless type (Wnt)/β-catenin signaling pathwaycould be involved [31]. In chronic lymphocytic leukemia
cells, Salinomycin inhibits the Wnt signaling cascade by
blocking the phosphorylation of the Wnt co-receptor
lipoprotein receptor related protein 6 (LRP6) causing
impaired cell survival. These data are of great interest
because in several tumor entities, LRP6 is over-
expressed [36]. Even if not completely understood, Wnt
signaling might also play an important role in the
Figure 5 Enduring reduced proliferation after treatment with Salinomycin. 1 x 103 human Mz-ChA-1, TFK-1 and EGI-1 cells were seeded in
microtitre plates and grown until confluence. Cells were cultured in the absence or presence of 1 mM Gemcitabine, 1 μM, 2 μM, 5 μM or 10 μM
Salinomycin. Treatment was performed for 24 (A) and 48 hours (B) or incubated for 48 hours under treatment and further grown with fresh
medium for another 48 hours (C). After pulsing with 3H-thymidine, cell cultures were maintained for an additional incubation period of 16 hours.
All three cell lines revealed significant reduced proliferation after 48 hours and high concentration of Salinomycin. This inhibition remained in
treated cells even after removal of the agent. Results are shown as summary of 3 independent experiments as mean ± SD; * p < 0,05 compared
with control.
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of several Wnt pathway inhibitors on human CC cells
has been demonstrated [38]. Additionally, it was
reported that Salinomycin induces apoptosis in prostate
cancer cells via accumulation of reactive oxygen species
and mitochondrial membrane depolarization [39]. Fur-
thermore, Salinomycin inhibits prostate cancer growth
via reduction of the expression of key oncogenes and in-
duction of oxidative stress in cultured prostate cancercells [32]. Taken together, several mechanisms are sup-
posed to be responsible for the effects of Salinomycin to
human cancer cells, which have to be investigated in
greater detail in the near future.
Furthermore, we demonstrate that the proportion
of non-apoptotic tumor cells following Salinomycin-
treatment is sustainable affected, characterized by impaired
tumor cell migration, reduced proliferation and cell cycle
accumulation. These observations are noteworthy due to
Figure 6 Salinomycin causes accumulation of human CC cells in the G2-phase. Mz-ChA-1, TFK-1 and EGI-1 cells were plated in 12-well
plates with 1 x 105 cells/well in culture medium. Cells were grown until confluence and then further cultured in medium (A) or presence of 1
mM Gemcitabine (B), 5 μM (C) and 10 μM Salinomycin for 24 hours (D). Cells were trypsinized and cell cycle was analyzed by flow cytometry. In
Mz-ChA-1 and TFK-1 cells, increasing concentrations of Salinomycin resulted in accumulation of cells in the G2-phase. In contrast, differences in
cell cycle phases were hardly observed in EGI-1 cells treated with Salinomycin. Results are shown as summary of 3 independent experiments as
mean ± SD.
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escaped apoptosis, including hyperproliferation. To further
characterize the effects induced by Salinomycin particularly
on the continuous apoptosis-resisting EGI-1 cells, we inves-
tigated the ability of human CC cells to migrate after drug
exposure. Tumor cell migration and therewith the ability to
form metastases is a hallmark of tumors. While Ketola
et al. have described impaired migration of prostate cancer
cells after treatment with Salinomycin in a wound-healing
assay [32]; this is the first report that migration through a
membrane is effectively inhibited. These observations dis-
close an additional anti-cancer effect of Salinomycin in
which all three cell lines are included.
Furthermore, the assessment of CC cell proliferation
with or without Salinomycin treatment revealed a signifi-
cant reduction of cell division in the presence of the agent.
Again, all three cell lines, even EGI-1 cells, have shown
this effect. We further demonstrate that Salinomycin-
treatment of human CC cells induced an enduring
reduced proliferation even after the abolition of treatment.
This long-lasting effect demonstrates that the proportionof human CC cells that have escaped apoptosis after
Salinomycin-treatment are affected permanently. These
observations might be of particular importance for the po-
tential clinical use of Salinomycin in the future as a pro-
longed effect of Salinomycin in patients with CC could
also be expected.
In addition, we were able to correlate the anti-
proliferative effects of Salinomycin with the results of the
cell cycle analyses. The impact of Salinomycin on human
CC cells is reflected by cell cycle accumulation in the G2-
phase. This finding is noticeable because others have
demonstrated that treatment with Salinomycin in equal
concentrations is associated with accumulation in the pre-
G1-phase, indicating increased apoptosis [17] Further-
more, in pre-treated human breast cancer with anti-
mitotic drugs, Salinomycin abolishes G2-arrest and
aneuploid cell formation [17,40]. In contrast, radiation-
treated breast cancer cells accumulate in the G2-phase
after treatment with Salinomycin [41]. Interestingly,
Salinomycin-induced apoptosis in human leukemia cells is
not accompanied by cell cycle arrest at all [20]. Thus, in
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cin on cell cycle are not consistent between human tumor
cells of different origin. This again demonstrates the exist-
ing nebulosity concerning the biochemical mechanisms
affected by Salinomycin.
Demonstrating the capability of Salinomycin to induce
apoptosis and to interfere with tumor cell motility and
proliferation in human CC cells, a potential and promis-
ing therapeutical approach for the treatment of CC
might be discovered. Particularly, cancer entities with
such calamitous prognosis like CC are tremendously
dependent on innovative and sufficient therapy concepts.
Thereby different human CC cell lines should be ana-
lyzed in regard to their susceptibility to Salinomycin-
treatment. Furthermore, animal models have to be
developed to investigate the impact of Salinomycin
in vivo. To what extend Salinomycin will achieve to be a
candidate for anti-cancer therapies in the future remains
to be seen. Given that lethal intoxication in humans and
animals are described [42-44], potential clinical studies
must be planned very thoughtful. Thus, finding the dos-
age of Salinomycin will be crucial for its application in
prospective therapeutical regimes.
Conclusions
Salinomycin exhibits anti-tumor effects on human CC
in vitro. Therefore, it should be considered as an innova-
tive approach for the treatment of CC in the future and
is worth to design further studies to proof practicability.
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